Manuscript

Robert Adamson’s final book is a search for recognition and a poetic tribute to his love of nature

Retrieved on: 
Tuesday, April 23, 2024

Birds and Fish: Life on the Hawkesbury – Robert Adamson (Upswell) In 2004, Adamson published Inside Out: An Autobiography.

Key Points: 
  • Birds and Fish: Life on the Hawkesbury – Robert Adamson (Upswell) In 2004, Adamson published Inside Out: An Autobiography.
  • Adamson grew up in Neutral Bay on Sydney’s lower north shore, which afforded him ample opportunity to pursue his interest.
  • It is a terrifying, beautiful scene, recounted not by the fallen boy, of course, but the poet he became.
  • What I think I was aiming for when I stared into each bird’s eyes was some flicker of recognition, some sign of connection between us.
  • What I think I was aiming for when I stared into each bird’s eyes was some flicker of recognition, some sign of connection between us.
  • Theories of recognition have a long history, which in the Western tradition date back at least as far as Hegel.
  • Read more:
    Poetry goes nuclear: 3 recent books delve into present anxieties, finding beauty amid the terror

Blunt and honest

  • This was the year of Mr Roberts, the teacher who introduced me to poetry and what they called nature studies.
  • This was the year of Mr Roberts, the teacher who introduced me to poetry and what they called nature studies.
  • It helped, too, that Mr Roberts “knew a bit about birds” and that he was encouraging about projects and assignments.
  • The young Adamson lights up, a recognition undimmed, even when a new teacher tells him “to forget [his] ambition”.
  • Nature was blunt and honest.
  • There was no third party, no good manners, no god involved – no reasoning or theology, let alone spelling and maths.
  • Nature was blunt and honest.
  • It is to do with the field of being; you can project yourself back to the original lores, rites and rituals.
  • It is to do with the field of being; you can project yourself back to the original lores, rites and rituals.


Craig Billingham has previously received funding from The Australia Council for the Arts (now Create Australia).

EQS-News: HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Wednesday, April 10, 2024

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • "The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans," emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Verana Health to Reveal Results from Largest Pediatric Intraocular Lens Study, Funded by the FDA, During AAPOS 2024

Retrieved on: 
Tuesday, April 9, 2024

Verana Health led the analysis utilizing real-world data from the Academy IRIS Registry – one of the largest specialty society clinical data registries in all of medicine.

Key Points: 
  • Verana Health led the analysis utilizing real-world data from the Academy IRIS Registry – one of the largest specialty society clinical data registries in all of medicine.
  • “The results of this study underscore the transformative potential of high-quality, curated real-world data in generating real-world evidence to enhance treatments and improve patients’ lives,” said Sujay Jadhav, CEO of Verana Health.
  • “We thank the FDA for the opportunity to lead this study, and we extend our appreciation to the Academy for its partnership.
  • Verana Health utilized its clinician-directed and artificial intelligence-enhanced population health data engine, VeraQ ®, to analyze curated, de-identified IRIS Registry data on pediatric cataract surgeries, amplifying the depth and accuracy of the study's insights.

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Retrieved on: 
Thursday, April 4, 2024

The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.

Key Points: 
  • The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.
  • The paper describes Sensei Biotherapeutics’ approach to the discovery and development of SNS-101, which was designed to potently and selectively target the active protonated form of VISTA, a protein that plays a significant role in suppressing T-cell activation.
  • SNS-101 is designed to block VISTA by inhibiting its interaction with PSGL-1 on T-cells resulting in T-cell activation.
  • The manuscript published in Nature Communications is entitled “VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response,” and can be found here: https://rdcu.be/dDF8x

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, April 1, 2024

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Moreover, the neflamapimod treatment effects on GFAP were correlated to clinical outcomes, assessed by the CDR-SB.
  • Cash Position: As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compared to $4.1 million as of December 31, 2022.
  • This increase was attributed to the RewinD-LB Phase 2b clinical study in DLB which began in the first quarter of 2023.
  • Net Loss: Net Loss was $2.2 million for the year ended December 31, 2023, compared to a net loss of $5.8 million for year ended December 31, 2022.

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Friday, March 29, 2024

PALO ALTO, Calif., March 29, 2024 (GLOBE NEWSWIRE) --  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Vincerx presented preclinical data at the 2023 AACR Annual Meeting demonstrating significant activity in patient-derived xenograft (PDX) lymphoma mouse models.
  • Vincerx shared preclinical data at the 2023 ASH Annual Meeting showing superior activity and safety compared with commercially available B-cell targeted ADCs.
  • For the fourth quarter and full year 2023, Vincerx reported a net loss of $4.9 million, or $0.23 per share, and a net loss of $40.2 million, or $1.89 per share, respectively.
  • For the fourth quarter and full year 2022, Vincerx reported a net loss of $13.8 million, or $0.65 per share, and a net loss of $63.0 million, or $3.00 per share, respectively.

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Retrieved on: 
Thursday, March 28, 2024

“In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.

Key Points: 
  • “In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.
  • We believe that we are well-positioned, both financially and scientifically, to execute our strategic plan with enhanced capabilities and resources.
  • For the year ended December 31, 2023, the Company received a total of approximately $1.3 million in connection with the sale of Alphazyme LLC.
  • Other Income: For the year ended December 31, 2023, the Company had a gain of approximately $1,018,000 from the sale of the Company’s equity interest in Alphazyme, LLC.

JenaValve Announces Publication of ALIGN-AR Pivotal Trial Results in The Lancet

Retrieved on: 
Thursday, March 28, 2024

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the publication of results from the ALIGN-AR Pivotal Trial in The Lancet .

Key Points: 
  • IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the publication of results from the ALIGN-AR Pivotal Trial in The Lancet .
  • As presented at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium, the ALIGN-AR trial met prespecified non-inferiority criteria for its primary safety endpoint and primary efficacy endpoint.
  • The positive outcomes reported from the ALIGN-AR trial in The Lancet usher in a new era for these patients.” Said Duane Pinto, MD, MPH, Chief Medical Officer at JenaValve.
  • Results from the study are intended to support a Premarket Approval submission to the U.S. Food and Drug Administration (FDA).

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

Retrieved on: 
Tuesday, March 26, 2024

The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO.

Key Points: 
  • The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO.
  • "The study characterized the in vitro activity of a monoclonal antibody (mAb) produced by C1 cells (designated "HuMab 87G7") and demonstrated its protective efficacy for both prophylactic and therapeutic applications in hamsters and non-human primates without causing antibody-mediated enhanced virus replication.
  • A mounting body of evidence, from both ourselves and an expanding community of scientists worldwide, supporting the use of Dyadic's C1 expression system as a versatile production platform.
  • To view the online publication of “Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models”, please visit nature communications or follow the link below:

Body armour made from silk is being developed – but this apparently cutting-edge idea is centuries old

Retrieved on: 
Tuesday, April 9, 2024

The researchers modified the genes of silkworms to make them produce spider silk instead of their own silk.

Key Points: 
  • The researchers modified the genes of silkworms to make them produce spider silk instead of their own silk.
  • Harnessing the properties of spider silk has been a longstanding aim because the material is as strong as steel, yet also highly elastic.
  • However, the idea of using silk to make bulletproof vests is not a new idea.
  • Five years later, Dr Goodfellow published further observations in “Notes on the Impenetrability of Silk to Bullets” in a journal called The Southern California Practioneer.
  • Using Goodfellow’s findings, the Catholic priest Casimir Zeglen (1869–1927) would later invent a silk bulletproof vest.
  • But the potential for silk as ballistic body armour had been recognised more than two centuries earlier, by Leibniz.
  • Instead, he thought silk was the most promising material for a bulletproof fabric due to being lightweight, flexible, and strong.
  • His idea for silk bulletproof clothing therefore did not get off the drawing board.


Lloyd Strickland does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.